Hyperlipidaemia in cisplatin-induced nephrotic rats

Area of Science:

• Nephrology
• Toxicology
• Biochemistry

Background:

• Cisplatin is a widely used chemotherapeutic agent with known nephrotoxic effects.
• Nephrotoxicity can lead to alterations in lipid metabolism.
• Understanding these metabolic changes is crucial for managing cisplatin therapy.

Purpose of the Study:

• To investigate the impact of cisplatin-induced nephrotoxicity on serum and hepatic lipid profiles in rats.
• To assess the reversibility of these lipid alterations following cisplatin exposure.

Main Methods:

• Rats were administered a single dose of cisplatin (6 mg/kg) to induce nephrotoxicity.
• Serum creatinine, urea, and total bilirubin were measured as indicators of kidney and liver function.
• Serum and hepatic lipid concentrations, including total cholesterol, triglycerides, and lipoprotein fractions, were analyzed at 5, 10, and 15 days post-treatment.

Main Results:

• Peak nephrotoxicity, indicated by elevated serum creatinine and urea, occurred on day 5.
• This was accompanied by significant increases in serum total cholesterol (49%) and triglycerides (42%).
• Very low-density lipoprotein (VLDL) cholesterol doubled, while hepatic triglycerides accumulated significantly on day 5. All parameters normalized by day 15.

Conclusions:

• Acute, reversible nephrosis induced by cisplatin in rats is associated with significant dyslipidemia.
• Cisplatin-induced nephrotoxicity leads to reversible alterations in lipid metabolism, including elevated VLDL cholesterol and hepatic triglyceride accumulation.
• These findings highlight the transient nature of cisplatin-induced metabolic disturbances and their recovery post-treatment.